

Overview


Dexion Absolute Limited is a Guernsey registered, closed-ended investment company listed on the London Stock Exchange. Consistent with Harris Alternatives' Aurora LP, whose investment rationale, methodology and portfolio management are shared by the Company, the Company no longer has a target return as part of its investment objective. The Company's investment objective is to generate consistent long-term capital appreciation with low volatility and little correlation with the general equity and bond markets through a portfolio having a diversified risk profile. The Company seeks to achieve this through investment in an actively managed portfolio of hedge funds diversified by investment strategy, style and manager. The Company's shares are denominated in Sterling, Euros and US Dollars and the Company implements a hedging policy to protect the Sterling and Euro value of its US Dollar denominated investments.

Monthly commentary

Global equity markets recovered sharply in November following a challenging October. U.S. equity markets rallied strongly due primarily to favourable corporate earnings reports, declining energy prices, and signals from the Fed of a slowdown in the pace of interest-rate rises. Overseas, encouraging economic reports lifted European markets, while Asian indices posted some of the strongest equity returns globally, particularly in Japan and Korea. Implied volatilities of U.S. and European equities declined following their sharp advances in October. In fixed-income, Treasury prices generally rose, while the yield curve continued to flatten. Finally, reflecting the rise in U.S. interest rates, the dollar gained further ground against both the Euro and the yen, reaching its highest levels since 2003.

During November, against a favourable backdrop for stock selection, nearly all our **hedged equities** managers recorded positive returns. Long exposure to basic materials stocks was a notable source of returns, as were holdings in technology, homebuilding, mining, and energy equities. Our European managers captured sizable profits from long positions in financial-services stocks, while our Asian managers benefited from their exposure to equities in Japan and Korea. Our **opportunistic** managers were strong performers during November, capturing returns in both developed and emerging markets. In fundamental equities, holdings in U.S. banks and other financial services companies were large contributors to returns as these stocks outperformed the markets. Elsewhere, our managers' event-driven portfolios produced notable gains from positions in a pharmaceutical firm, an optical-surgical device maker, a mining-related company, and a major fast-food restaurant chain. In emerging markets, positions in Latin American debt, particularly in Brazil, drove the performance of our manager dedicated to these markets. Equity holdings in Eastern Europe also advanced due to strengthening investor confidence. Although the credit markets were relatively quiet, our **distressed securities** managers produced a gain during November. The market's optimism for an end to the Fed's tightening cycle sparked a modest rally in high-yield securities towards the end of the month. Positive company-specific developments and a favourable equity market environment drove our **equity strategies** managers' returns during November. One manager's position in a biotechnology firm continued to rise following strong quarterly results at the end of last month. Another manager's holdings in a medical-products supplier surged in anticipation of a pending FDA approval of one of the company's products. Additionally, the shares of an owner/operator of luxury hotels and resorts advanced after one of our managers disclosed a large position in the company. Our **tactical trading** managers registered a positive return during November. One manager extracted gains from positions in the U.S., Japanese, Korean, Brazilian, and Latin American equity markets, while European fixed-income trading was profitable for another. In addition, long positions in the U.S. dollar versus the Euro and yen also proved fruitful. A strong equity market, coupled with the significant out performance of highly-speculative, small and mid-cap stocks, created a headwind that proved too stiff for our **short sellers** to overcome during November. Losses were generated across nearly all sectors but were more heavily concentrated in technology, consumer, and financial-services stocks. Despite a sharp decline in implied equity volatility during November, our **relative value arbitrage** managers posted a solid return. Energy trading was again an important driver of performance. Electricity and natural gas trading benefited from high levels of market volatility, while a spike in crude oil prices towards the end of the month also led to profits. U.S. and foreign convertible bond arbitrage was generally profitable as new issuance mitigated declines in the secondary market. Asian convertibles, most notably Japanese securities, were especially strong performers due to the continued strength in the Asian equity markets.

Outlook - as 2006 approaches, we find that most hedge fund strategies offer attractive opportunities, especially the stock-selection strategies that rely on fundamental analysis. We also believe our opportunistic and tactical trading managers should continue to profit from areas of market dislocations that they have identified. Historically tight credit spreads continue to restrict opportunities for our distressed securities managers. In relative value arbitrage, we continue to monitor the landscape for a resurgence of attractive and sustainable opportunities. Across all strategies we continue to search for managers capable of generating strong returns. The recent market environment has resulted in the volatility of the Company's NAV returns being lower than expected.



NAV 128.70p
Return +1.40%
Share price* 129.38p

NAV €1.8909
Return +1.16%
Share price* €1.9300

NAV \$2.3017
Return +1.32%
Share price* \$2.3325

Note:
* Closing mid-price at month end.
Opening NAV per £ share 98.25p,
€ Share €1.8325 and \$ Share \$2.2158.

Key facts

Manager
Dexion Capital
(Guernsey) Limited

Investment
Advisor
Harris Alternatives LLC

Investment
Consultant
Dexion Capital plc

Total net assets
£384.4m

Management Fee
1.50%

Performance Fee
10%
(trigger 3%)

Contact details

Dexion Absolute Limited
Arnold House
St Julian's Avenue
St Peter Port
Guernsey
GY1 3NF

Email
info@dexionabsolute.com


Website
www.dexionabsolute.com

Performance data


	November (%)	YTD ¹ (%)	ITD\$* (%)	Volatility\$* (%)	Sharpe\$* ^{^A}
Dexion Absolute £ Share NAV	1.40	7.60	9.70	2.93	1.84
FT All Share (TR) (£)	3.30	17.42	17.52	10.53	1.25
FT Govt All Stocks (TR) (£)	1.23	6.44	5.17	3.52	0.25
Dexion Absolute € Share NAV	1.16	3.19	-	-	-
MSCI Eurozone (TR) (€)	4.11	8.99	-	-	-
JPMorgan Eurozone Govt Bond Index (€)	-0.03	-0.72	-	-	-
Dexion Absolute US\$ Share NAV	1.32	3.88	-	-	-
MSCI World (TR) (US\$)	3.39	8.05	-	-	-
JPMorgan World Govt Bond Index (US\$)	-1.14	-4.09	-	-	-
HFRI Fund of Funds Index (US\$)	1.74	5.54	8.21	3.35	1.86

¹ Cumulative performance from inception for € and \$ Shares. § Insufficient data points for € and \$ Shares. * Annualised from inception date of DAB £, based on monthly data.
^{^A} Risk free rate is average 1M GBP LIBOR (4.31%) for GBP investments and average 1M USD LIBOR (1.96%) for USD investments.
Source: Bloomberg (data), Dexion Capital (calculation)


Net Asset Value performance



Share price performance




Portfolio as of 1 December 2005



	Number of funds
Distressed Securities	6
Equity Strategies	5
Hedged Equities	18
Opportunistic	6
Relative Value Arbitrage	3
Short Selling	8
Tactical Trading	5
Total	51

Historical NAV performance (%)

GBP	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2005	0.29	1.54	0.06	-0.87	0.88	1.38	1.51	0.86	1.75	-1.41	1.40		7.60
2004	1.39	0.96	0.38	-0.18	0.03	0.61	-0.06	0.39	0.86	0.41	1.70	1.38	8.13
2003	1.44	0.02	0.78	1.37	2.11	1.56	-0.48	0.27	1.48	0.72	0.31	2.39	12.59
EUR													
2005	-	-	-	-	-	-	1.28	0.67	1.64	-1.58	1.16		3.19
USD													
2005	-	-	-	-	-	-	1.37	0.82	1.74	-1.41	1.32		3.88



Share Class	Inception date	Bloomberg	Reuters	ISIN	Sedol	Total net assets
GBP	19 Dec 2002	DAB LN	DAB.L	GB0032287020	3228702	£332.36m
EUR	28 Jun 2005	DABE LN	DABx.L	GB00B0FXK920	B0FXK92	€49.52m
USD	28 Jun 2005	DABU LN	DABu.L	GB00B0FXL332	B0FXL33	\$31.79m

This report is issued by Dexion Absolute Limited and has been approved for the purposes of Section 21 Financial Services and Markets Act 2000 ("FSMA") by Dexion Capital plc, which is authorised and regulated by the Financial Services Authority in the United Kingdom. This document contains information only and relates solely to Dexion Absolute Limited ("the Company") whose securities are dealt in on The London Stock Exchange. It does not constitute an invitation to underwrite, subscribe or otherwise acquire or dispose of any securities in the Company and should not be construed as advice or a recommendation to any person to engage in any of the foregoing activities. It does not constitute an invitation to effect any transaction with the Company or any other person. Whilst certain of the information in this document may refer to the price of the Company's securities or the yield on them, past performance cannot be relied on as a guide to future performance.

The information in this report is based on information which is otherwise publicly available and, whilst the Company and Dexion Capital plc use all reasonable efforts to ensure the information in this report is accurate, and up to date, no representations or warranties are given as to the reliability, accuracy or completeness of the information in this report. Neither the Company nor Dexion Capital plc accept any liability for any loss or damage which may arise directly or indirectly from any use of or reliance on such information save in circumstances where such exclusion or restriction of liability would be expressly prohibited by the rules of the Financial Services Authority or any other applicable laws or regulations in England and Wales. In particular, recipients should note that, since many or all of Dexion Absolute's investments are unquoted, net asset value figures in relation to Dexion Absolute are based wholly or partly on estimates of the values of Dexion Absolute's investments provided by the investment managers or administrators of those underlying investments, which estimates may themselves have been subject to no verification or auditing process or may relate to a valuation at a date before the relevant net asset valuation for Dexion Absolute, or which have otherwise been estimated by Dexion Absolute's Investment Advisor. Other information in this report may be historic and/or may no longer be of relevance.

The information contained in this report which relates to the net asset value performance of Dexion Absolute may not be indicative of how Dexion Absolute's investments may perform in the future. Moreover the values of such investments may fluctuate considerably and the historic net asset values shown for Dexion Absolute take no account of the costs or practical difficulties of realising some or all of such investments. The value of investments mentioned in this report may go down as well as up and investors may not get back the amount invested. Information on past performance, where given, is not necessarily a guide to future performance. Changes in rates of exchange between currencies may cause the value of investments to decrease or increase. The information in this report is provided solely for information and does not constitute investment advice or personal investment recommendations. Investments mentioned in this report may not be suitable for all recipients and in each case potential investors are advised not to take any investment decision unless they have taken independent advice from a suitably qualified advisor.

Your attention is drawn to the Risk Factors set out in the Dexion Absolute prospectus dated 26 October 2005 and the fact that no securities are currently being offered by the Company and that certain information in the above prospectus may now be out of date.

This report may not be mailed or distributed or redistributed or otherwise sent into, and does not constitute any offer to sell or the solicitation of any offer to buy securities, in any territory. In particular, the information in this report is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States of America to or for the benefit of United States persons being resident in the United States of America or partnerships or corporations organised under the laws of the United States of America or any state, territory or possession thereof. The shares in Dexion Absolute have not been, and will not be registered under the United States Securities Act 1933.